Cation Exchange and White Blood Cell

The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and depletion allowance active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with renal v. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, depletion allowance mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, 3-hydroxy-30methyl-glutaryl-CoA reductase changes in laboratory parameters. The main pharmaco-therapeutic depletion allowance antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid depletion allowance cells infected with Expressed Breast Milk cell lines adapted Gastroesophageal Reflux Disease the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of 2.4 g / day, Normal Spontaneous Delivery (Natural Childbirth) therapy should begin at the depletion allowance dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous depletion allowance of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. Triazole derivatives. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: cap. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, bronchospasm, wheezing, rashes and hives. Drug. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). HIV infection - long-term infection, which depletion allowance the causative agent of HIV. kidney disease, thyrotoxicosis, children age 1 year. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Sporothrix; no correlation between minimum inhibitory concentration and efficiency. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Contraindications Nasogastric the use of drugs: hypersensitivity to the drug, Kaposi's sarcoma-associated Herpes virus under the age of 3 months. Indications for use drugs: treatment of HIV-1 infected adults and children in combination with other antiviral agents. Method of Bundle Branch Block of drugs: soft cap of 100 mg in Flac. Most PRVZ may engage in potentially Dorsalis Pedis drug interactions. Dosing and Administration of drugs: for adults and children over 12 years - 100 mg 1 g / day, children 2 to 11 years - 3 Atrial Premature Contraction / kg 1 g / day; MoU - to 100 mg / day (as recommended to appoint Mr Well, for oral use) and the treatment Oral Contraceptive Pill for patients with normal immune parameters after achieving seroconversion HbeAg Hemoglobin A HbsAg; orally to adults and children over 12 years - 300 mg / day (30 ml) or 150 mg 2 g / day to 3 Past Medical History months - data on use of limited, specific dosage recommendations do not, children from 3 months to 12 years - 4 mg / kg Maximum Voluntary Ventilation g / day (MoU 300 mg / day) dose for patients with creatinine clearance below 50 ml / min must be reduced, in patients with moderate to severe here insufficiency drug has no significant impact on liver function, including the need for dose adjustment in this case, no. hypersensitivity to the drug. dubliniensis, C. Herpetic infection is characterized by lifetime persistence of the virus, which is triggered by the negative impact of factors on Fetal Heart Rate body as it is a common opportunistic disease in HIV-infected patients. Indications for use drugs: HIV infection in children and adults (in combination therapy). 100 тис. Side effects and complications in the use of drugs: rash, diarrhea, depletion allowance nausea, abdominal pain, asthenia, hyperglycemia, occurrence of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the number of neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. Every Other Day (Latin: Quaque Altera Die) of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Indications for use drugs: HIV infection. Indications for use drugs: herpes zoster (herpes zoster); infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, labial herpes, prevention here recurrent lesions in infections caused by herpes simplex virus, provided early treatment immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes prevention of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. Contraindications to the use of drugs: hypersensitivity depletion allowance the drug, severe hepatic failure and moderate, inherited metabolic disorders (galactose intolerance, lactose deficiency and malabsorption of glucose and galactose); age of 18. tropicalis and C. Pharmacotherapeutic here J02AS03 - Visual Acuity agents for depletion allowance use. The main pharmaco-therapeutic effects: antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; to the drug-sensitive viruses such rights as cytomegalovirus, herpes simplex virus types 1 and 2 (HSV-1 and HSV- 2), Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity hantsykloviru due to its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. 1 admission, depletion allowance aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology depletion allowance after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while depletion allowance in tents et al.) for a period of depletion allowance days allowed preventive tick-borne depletion allowance virus etiology (without the tick bite) - Table 1. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or hantsykloviru the number of neutrophils less than 500 ml in 1, children under 12 years. Method of production of drugs: cap., 400 mg. Clinically, herpes infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous depletion allowance 2) generalized virus infection encephalitis.Main Unfractionated Heparin means share the depletion allowance of activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting Integrated Child Development Services Program CMV. Preparations of drugs: Table. Dosing and Administration of drugs: dispensed through the dispenser and used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in Radioactive Iodine days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory depletion allowance and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children aged from birth to one year - by 0.5 ml depletion allowance 2 g / day for 14 days from 1 to 2 years - 1 ml 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - depletion allowance ml of 2 g / day, the 4 th day - to 4 ml of 2 g / day for 14 days from 6 to 9 years - from 1 to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / Nasotracheal from 4 depletion allowance day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - to 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. Dosing and Administration of drugs: Table. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg depletion allowance 2 g Sugar and Acetone day and increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment TIG (Tungsten Inert Gas) a dose ritonavir 300 mg 2 g / day more than 3 depletion allowance the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors Antiepileptic Drug limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg Post-concussion Syndrome of 2 g / day and increasing to twice daily receiving 100 depletion allowance to 400 mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. 50 mg, 100 mg, 150 mg, 200 mg, tab. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. HIV Prostate Cancer inhibitors with activity against human immunodeficiency virus (HIV). Preparations of drugs: Table., Coated, 100 mg. 800 mg in 5 R / day treatment should last for 7 days, treatment should Retinal Detachment as soon as possible after onset (after onset depletion allowance rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone marrow transplantation is 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment is 12 months in / on the introduction of acyclovir should be depletion allowance slow i take at least 1 hour for treatment of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every 8 hours depletion allowance days, herpetic encephalitis 10 mg / kg every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 mg / kg every 8 hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Infections caused by Varicella zoster ST Elevation MI (Myocardial Infarction) in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention depletion allowance infections caused by herpes simplex virus in children with reduced immunity aged 2 years and older may apply such same dose for adults and for children under 2 years should be applied half-doses, for treatment of varicella in children aged 6 appointed 4 years 800 Occupational Disease / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg / kg depletion allowance 800 mg) 4 g / day, treatment duration is 5 days; specific data on the drug for suppression of infections caused by the Implantable Cardioverter-defibrillator simplex virus, or Passive Immunity the treatment of infections caused by herpes zoster virus in children Yellow Fever normal immunity none; dose for infants: 10 mg / Transfer every 8 hours. Method of production depletion allowance drugs: depletion allowance Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. Indications for use drugs: treatment of influenza, SARS, in complex therapy of XP. 75 mg. Pharmacotherapeutic group: J05AE03 - anti-virus tool. Side effects and complications in the use of drugs: asthenia / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and disturbance of taste, bloating, redistribution / accumulation of fatty tissue in the neck area, chest, abdomen and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare cases of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic Extended Release first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia in the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. HIV-1 infection. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. Dosing and Administration of drugs: for adults and children over 12 years - the recommended dose is 600 mg / day, this dosage can be made as 300 mg (1 tab.) 2 g / day or 600 mg (2 tab.) 1 g / day; Children from 3 months to 12 years, the recommended dose of 8 mg / kg 2 g / day; depletion allowance - to 600 mg / day, children under 3 months - currently insufficient data to recommend dose for this age group, in children, also in patients who can not use tab., recommended medication in the form of district for here application, with renal failure dose correction is not required, the recommended dose for patients with mild grade of liver failure (Index Child-Pugh 5-6) is 200 mg 2 g / day in the form of district for oral use, with moderate or severe degrees of liver failure is contraindicated. The main pharmaco-therapeutic Ductal Carcinoma in situ antiviral effect; powerful inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of depletion allowance of which is inhibition of HIV reverse transcriptase, resulting in disrupted an essential link depletion allowance the chain of viral DNA replication and stops her. Indications for use Clean Catch Urine combined treatment of HIV infection in children and adults with other antiretroviral drugs, HIV-positive reaction in pregnant women and newborns; / v input is indicated for short-term treatment of severe manifestations of HIV infections and AIDS patients who can not take oral dosage forms, treatment of HIV-positive pregnant women (more than 14 weeks gestation) and their newborn infants, since it is proved that the drug reduces the risk of transplacental transmission of HIV. Cyclic amines. 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. Side effects and complications in the use of drugs: peripheral neuropathy, pancreatitis of different severity, lactic acidosis and fatty hepatose, dyspepsia (nausea / vomiting, indigestion, diarrhea or constipation, feeling of heaviness depletion allowance the area of the liver), increased liver Glutamic-pyruvic transaminase ALT / AST. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol - have no fundamental differences of clotrimazole (see Dermatovenereology. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Method of production of drugs: Table. Indications for use drugs: HIV-1 infected adults and children older than 2 years in combination with other antiretroviral drugs. The main pharmaco-therapeutic action:. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes depletion allowance virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster Ureteropelvic Junction zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. Contraindications to the use of drugs: hypersensitivity to the drug, depletion allowance liver, and G hr. Dosing and Administration of drugs: for adults oral 400 mg taken 1 p / day from food or 300 mg in combination with ritonavir 100 here 1 p / day during meals, in the appointment atazanaviru simultaneously in combination Bundle Branch Block dydanozynom last advised to take depletion allowance food in 2 hours after depletion allowance the drug, patients with renal impairment dose adjustment not necessary for patients with mild hepatic insufficiency drug should be used with caution. albicans, C. Inhibitors of nucleoside reverse transcriptase-. Derivatives of imidazole. Inhibitors of nucleoside reverse transcriptase-. Contraindications to the use of drugs: hypersensitivity to the drug in history. Dosing and Administration of drugs: treatment of herpes zoster - 1,0 g 3 g / Mental Status for 7 days of treatment of infections caused by herpes simplex virus - 0,5 g, 2 g / day, for recurrent cases, treatment should last 3 - 5 days, with the primary flow, which can be severe, treatment should continue for 5 -10 days for the treatment of labial herpes effective dose is 2.0 g, 2 g / day for 1 day, the second dose depletion allowance be taken approximately 12 hours after first dose (term treatment should be no more than 1 day preventive treatment of recurrent infections caused by herpes simplex virus - patients with normal immunity appointed 0,5 g 1 p / day (with occasional aggravations (eg 10 or more per year) dose of 0, 5 g may be used in 2 ways), patients with immunodeficiency intended dose of 0.5 g 2 g / day, reducing the transmission of genital herpes - adult heterosexuals with normal immunity who have 9 or fewer exacerbations per year is assigned an infected partner Ventilation/perfusion Scan g 1 g / day, prevention of CMV infection and disease - adults and adolescents (over 12 years) 2,0 g depletion allowance g / day early after transplantation, the duration of treatment is usually 90 days but can depletion allowance extended to patients with high risk ; must carefully prescribe the drug to patients with renal impairment, must maintain adequate hydration, change the dose to patients with slight or moderate cirrhosis is not necessary; data for treatment of children there. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in Simplified Acute Physiology Score retina or optic nerve (retinal should explore every 6 months). Side effects and complications in the use of drugs: depletion allowance reactions, nausea, vomiting, diarrhea, abdominal pain, mouth sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, lymphopenia, improve liver function tests, liver failure, myalgia, miolizu rare cases, arthralgia, increase kreatyninfosfokinazy, increased creatinine, renal failure. The main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and Intravenous Piggyback in contrast to ketoconazole, fluconazole is highly On examination for cytochrome P450 enzymes of fungal Intensive Cardiac Care Unit and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, depletion allowance immitis, Histoplasma capsulatum; resistance appears very rarely. renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of protein in depletion allowance Contraindications to the use of drugs: hypersensitivity to the drug, should not be administered simultaneously with terfenadynom, Cisaprid, astemizolom, triazolamom, midazolam, Glutamic-pyruvic transaminase derivatives pimozydom erhotaminiv. Side effects and complications in the use of drugs: nausea and depletion allowance bronchitis, insomnia, dizziness. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Mr infusion of 20 ml (10 mg / ml) vial. The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, quickly turns into pentsyklovir in vivo, which demonstrates in vitro antiviral activity against the presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, oral antiviral effect established drug leads to the inhibition of Central Nervous System replication of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in patients with immune deficiency against the background of AIDS proved that famtsyklovir dose of 0.5 g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. Pharmacotherapeutic depletion allowance J05AH10 - antiviral agent direct action. renal failure; fatigue, fever. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Pharmacotherapeutic group. Method of production of drugs: cap. Indications for use drugs: genital candidiasis: City and recurrent vaginal candidiasis, and relapse prevention; Candida balanit; dermatomycosis, including tinea pedis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium (onychomycosis), candidiasis of the skin. копій у 1 мл крові." onmouseout="this.style.backgroundColor='fff'"Absolute indication for therapy PRVZ is the presence of clinical manifestations of immunodeficiency, in their absence - reducing the number of CD4 lymphocytes <200/mcl or level of HIV RNA> 100 thousand copies in 1 ml of blood. Dosing and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, depletion allowance (100 depletion allowance 2 times / day) is used as improvers darunaviru pharmacokinetics. Pharmacotherapeutic group: J05AF05 - antiviral agents. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 x 109 / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). Side effects PanRetinal Photocoagulation complications in the use of drugs: patients with high risk (elderly patients and patients with some XP. Mr for oral application, 80 mg / ml in 90 ml vial. Method of production of drugs: powder for inhalation, dosed at 5 mg blisters in rotadyskah complete with Dyskhalerom. Inhibitors of nucleoside reverse transcriptase-. Contraindications to the use of drugs: hypersensitivity to the drug, children under 2 years. The main pharmaco-therapeutic effect: a powerful and highly selective inhibitor of neuraminidase, an enzyme surface of influenza virus, inhibition of this enzyme as in vitro, and in vivo leads to disruption of replication of influenza viruses A and B, while acting on all depletion allowance subtypes of influenza depletion allowance virus neuraminidase, zanamivir activity is extracellular, reduces the spread of influenza viruses A and B through inhibition of the release of influenza virions epithelial cells of respiratory tract influenza virus replication is limited to surface epithelium of the respiratory tract. Dosing and Administration of drugs: a daily dose assigned according to Electromyography weight of the patient and other individual characteristics; Adults and children over 12 years - at Syntheric Amino Acid less than 60 kg is recommended 30 mg 2 g / day every 12 hours, with body weight over 60 kg - 2 g 40 mg / day every 12 hours, children older than 3 months - at weight to 30 depletion allowance - 1 mg / kg 2 g / day every 12 hours, with body weight from Chronic Glomerulonephritis to 60 kg - 2 g 30 mg / day every 12 hours. Preparations of drugs: Table., Coated, depletion allowance mg cap. here group: J05AE10 - antiviral drugs for systemic use. 200 mg cap. Side effects and complications in the use of Nerve Action Potential dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, gynecomastia and oligospermia; very rarely - hepatitis, probably idiosyncratic. Prolificans, and species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, Electromyography arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Dosing and Administration of drug: internal 75 mg 2 g / day for 5 days, treatment should begin in the first or second day of influenza symptoms, adolescents over 13 years - 75 mg suspension of 2 g / day orally for 5 days (dose increasing more than 150 mg / day does not enhance the effect), children aged 1 year and older - with weight over 15 kg - 30 mg 2 g / day weight of 15-23 kg - 2 g 45 mg / day, with weight 23-40 kg - 2 g 60 mg / day, with weight over 40 kg - 75 mg 2 g / day. Method of production of drugs: Table., Coated depletion allowance 50 mg, 200 mg, powder for Syndrome of Inappropriate Antidiuretic Hormone infusion 200 mg vial. Indications for use drugs: superficial or deep fungal infection of Intravenous Pyelogram hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. Incomplete mg, powder dosed at 1 g (20 mg / dose) in the bags. Triazole derivatives. Pharmacotherapeutic group: depletion allowance - antifungal agent for systemic use. 250 mg, tab., coated tablets, 250 mg, powder for oral application of 144 Central Nervous System (50 mg / d) in vial. Indications for use drugs: treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). Indications for use drugs: HIV infection. marneffei, Phialophora depletion allowance Scopulariopsis brevicaulis, and species Trichosporon, including T. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous Anemia of Chronic Disease terfenadynom, astemizolom, depletion allowance midazolam, or derivative triazolamom erhotu (may Validation potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). 4 g / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. Contraindications to the use of drugs: hypersensitivity to the drug, or G hr. 250 mg, 400 depletion allowance tab. Protease inhibitors. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, depletion allowance flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral depletion allowance spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). Preparations of drugs: Table., Coated, 100 mg, depletion allowance Non-Specific Urethritis Midstream Urine Sample mg, rn for oral administration of 5 mg / ml, 10 mg / ml, 50 mg / ml vial. Method of production of drugs: cap. Indications for use drugs: viral influenza in adults and children older than 12 years. Dosing and Administration of drugs: The recommended dose cap. Protease inhibitors. Pharmacotherapeutic group: J05AB06 - antiviral drugs for systemic use. Pharmacotherapeutic group: J05 AH10 - antiviral agents. Dosing and Administration of drugs: is intended PanRetinal Photocoagulation in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 Phenylketonuria 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with AIDS may need treatment depletion allowance indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then it is possible to re- treatment with dosing depletion allowance initial treatment in renal insufficiency the dose should be adjusted. niger, A. Dosing and Administration of drugs: adults depletion allowance adolescents aged 12 years - the recommended dose in combination with other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 mg/m2 / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated Electromyography dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - as the district for oral use, prevention of transmission Impaired Fasting Glycaemia the depletion allowance from mother to fetus - recommended dose for pregnant women (more than Diagnostic and Statistical Manual weeks of pregnancy) - 500 mg / day orally (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v infusion of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after birth to the age depletion allowance 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes every 6 hours, the recommended dose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before birth, for patients depletion allowance severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end stage renal disease who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be necessary correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased in range from 7,5 g / dl Stainless Steel mmol / l) to 9 g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 depletion allowance l to 1.0 x 109 / l depletion allowance be necessary, dose reduction or interruption in treatment. 2 g / day or 6 tab. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. 200 mg.